formoterol fumarate

(redirected from Foradil Aerolizer)

formoterol fumarate

Atimos Modulite (UK), Foradil (UK), Foradil Aerolizer, Oxeze (CA), Oxis (UK), Perforomist

Pharmacologic class: Sympathomimetic; long-acting, selective beta2-adrenergic receptor agonist

Therapeutic class: Bronchodilator

Pregnancy risk category C


Stimulates intracellular adenylate cyclase, relaxing bronchial smooth muscle and inhibiting release of mediators of immediate hypersensitivity


Capsules for oral inhalation (used with Aerolizer inhaler): 12 mcg

Indications and dosages

Long-term maintenance of asthma; prevention or long-term maintenance of bronchospasm in patients with chronic obstructive pulmonary disease

Adults and children ages 5 and older: Contents of 1 capsule inhaled orally via Aerolizer q 12 hours

Acute prevention of exercise-induced bronchospasm (on occasional, as-needed basis)

Adults and children ages 5 and older: Contents of 1 capsule inhaled orally via Aerolizer at least 15 minutes before start of exercise. Wait 12 hours after initial dose before giving repeat dose.


• Hypersensitivity to drug or its components
• Tachyarrhythmias


Use cautiously in:
• acute asthma symptoms, deteriorating asthma, cardiovascular disorders, seizure disorders, thyrotoxicosis, diabetes, possible hypokalemia
• patients older than age 75
• labor
• pregnant or breastfeeding patients
• children younger than age 5.


• Be aware that drug is not intended for acute asthma attacks.
• Use capsules only with Aerolizer inhaler supplied.
• Keep capsules in blister until immediately before use.

Make sure patient doesn't swallow capsules.

Adverse reactions

CNS: tremor, dizziness, insomnia, anxiety

CV: chest pain

EENT: sinusitis, pharyngitis, tonsillitis

GI: dry mouth

Metabolic: hypokalemia, hyperglycemia

Musculoskeletal: muscle cramps, back pain, leg cramps

Respiratory: bronchitis, chest infection, dyspnea, upper respiratory tract infection, increased sputum

Skin: pruritus, rash

Other: dysphonia, viral infection, fever


Drug-drug.Adrenergics: potentiation of formoterol's sympathomimetic effects

Beta-adrenergic blockers: partial or total inhibition of formoterol's effects

Cardiac glycosides, methylxanthines, potassium-wasting diuretics, steroids: potentiation of formoterol's hypokalemic effects, increased risk of arrhythmias

Disopyramide, MAO inhibitors, quinidine, phenothiazines, procainamide, tricyclic antidepressants: prolonged QTc interval, increased risk of ventricular arrhythmias

Halogenated hydrocarbon anesthetics: increased risk of arrhythmias

Levodopa, levothyroxine, oxytocin: impaired cardiac tolerance of formoterol

Drug-diagnostic tests.Blood glucose: increased level

Potassium: decreased level

Drug-behaviors.Alcohol use: impaired cardiac tolerance of formoterol

Patient monitoring

• Monitor pulmonary function test results.
• Monitor potassium and glucose levels.

Patient teaching

• Teach patient how to use capsules and Aerolizer inhaler provided.
• Instruct patient to keep capsules in blisters until immediately before use.
• Caution patient not to swallow capsules.
• Tell patient not to use drug for acute asthma attacks.

Instruct patient to contact prescriber immediately if difficulty in breathing persists after using drug or if condition worsens.
• Caution patient to take drug exactly as prescribed and not to stop therapy even if he feels better.
• Tell patient to consult prescriber if he has been taking inhaled, short-acting drugs on a regular basis.
• Advise female patient to tell prescriber if she is pregnant or breastfeeding or if she plans to become pregnant.
• Caution patient to avoid alcohol during therapy.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs, tests, and behaviors mentioned above.

formoterol fumarate

(fôr-mō′tə-rôl′, -rōl′)
A drug used in the treatment of asthma, the prevention of bronchospasm, and the maintenance treatment of chronic obstructive pulmonary disease.

formoterol fumarate

a beta-adrenergic agonist used to treat chronic obstructive pulmonary disorder, maintain and treat asthma, and prevent exercise-induced bronchospasm.
Mentioned in ?
References in periodicals archive ?
In October 2002, Schering-Plough and Novartis announced an agreement giving Schering-Plough exclusive United States distribution and marketing rights to Novartis' FORADIL AEROLIZER.
FORADIL AEROLIZER, a long-acting beta2 agonist for asthma and chronic obstructive pulmonary disease.
Foradil Aerolizer (formoterol fumarate), made by Novartis AG, is included in the health advisory.
FORADIL AEROLIZER should only be used as additional therapy for patients not adequately controlled on other asthma controller medications.
Promotion for Novartis' oral antidiabetic agent, Starlix, and its new asthma medication, Foradil Aerolizer, contributed to this increase in Novartis' total promotion.
In this Phase 2b study, patients with moderate-to-very severe COPD were randomized to receive one of two doses of PT003, PT001, one of two doses of PT005, Spiriva, Foradil Aerolizer (formoterol fumarate inhalation powder), or placebo.
The Foradil Aerolizer (formoterol inhalation powder), a long-acting, selective [beta]-2 adrenoreceptor agonist manufactured by Novartis Pharmaceuticals Corp.
today announced positive results from a randomized, double-blind, Phase 2b, dose-ranging study of its formoterol fumarate metered dose inhaler (FF MDI; PT005), a long-acting beta-2 agonist (LABA) compared to placebo and Foradil Aerolizer in patients with moderate-to-severe COPD.
Further, PT003 also showed superior bronchodilation compared to active comparators, Spiriva HandiHaler and Foradil Aerolizer.
The Phase 2b dose-ranging study will compare twice-daily dosing of PT003 against placebo, glycopyrrolate HFA-MDI (PT001), formoterol HFA-MDI (PT005), Spiriva HandiHaler (tiotropium bromide inhalation powder) and Foradil Aerolizer (formoterol fumarate inhalation powder) in patients with COPD.